Ascendis Pharma (ASND) Prices 2M Share Offering at $150/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as oil and yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Francisco Partners to acquire Weave Communications for $650M
BofA Securities Reiterates Buy Rating on Ascendis Pharma (ASND)
September 23, 2024 5:11 AM EDTBofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $191.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "We hosted an expert pediatric endocrinologist to discuss his views on ASNDs TransCon CNP in achondroplasia (ACH) following the recent topline ph 3 readout (see our Sep 16th note). Overall, our KOL was encouraged by the stat sig AGV... More
